Background
==========

Lumbar disc herniation (LDH) is a primary cause of low-back pain and unilateral leg pain, which is a degeneration and herniation of the nucleus pulposus of intervertebral disc \[[@b1-medscimonit-25-3728]\]. It is the most common cause of activity limitation in individuals under 45 years of age \[[@b2-medscimonit-25-3728]\]. With the clinical symptoms of lumbocrural pain, it occurs 18% of the normal population on average in China \[[@b3-medscimonit-25-3728]\]. Furthermore, more than 20% of patients need surgery to relieve prolonged or aggravated leg pain. Although some risk factors associated with LDH have been reported, its pathogenesis and etiology for the most part unclear. Objective epidemiological evidence suggests that the most determining individual factor in intervertebral disc degeneration is a family history \[[@b4-medscimonit-25-3728]\]. Varlotta et al. \[[@b5-medscimonit-25-3728]\] showed that the risk of LDH is estimated to be approximately 5 times greater in patients who have a positive family history.

The intervertebral disc is a fibrocartilaginous tissue, which provides stability and flexibility to the spinal column. It is composed of a central nucleus pulposus and a ring-like fibrous annulus fibrosus mainly composed of type I collagen, type II collagen, and proteoglycan, and providing tensile strength \[[@b6-medscimonit-25-3728],[@b7-medscimonit-25-3728]\]. Several researchers have reported that the excessive degradation and fibrosis of type I and type II collagen are the main causes of disc degeneration \[[@b8-medscimonit-25-3728]\]. These catabolic processes are thought to be mediated by soluble factors such as the pleiotropic cytokine interleukin-1 (*IL1*).

Interleukin-1 (*IL1*) is involved in the inflammatory process of LDH. IL-1β is an active form of IL1 during the inflammatory response, and its expression is increased in LDH patients \[[@b9-medscimonit-25-3728]\]. *IL1R1* encodes cytokine receptor for *IL1*, through combining with *IL-1* on the cell surface affects NF-κB signaling and upregulates inflammation \[[@b10-medscimonit-25-3728],[@b11-medscimonit-25-3728]\]. Millward-Sadler and others have suggested the expression of *IL1* and associated receptors in disc degeneration and shown that the*IL1R1* is expressed by normal disc cells, with upregulation of *IL1R1*, during degeneration \[[@b12-medscimonit-25-3728]\]. Christine et al. \[[@b7-medscimonit-25-3728]\] confirmed that *IL1* gene cluster mutation plays an important role in the pathogenesis of LDH. Nakki and colleagues \[[@b13-medscimonit-25-3728]\] found that the genetic variation rs2287047 in *IL-1R1* gene was associated with severe hand osteoarthritis. Osteoarthritis and LDH can be seen as having a similar etiological pathway, both of which involve the degeneration of collagen \[[@b14-medscimonit-25-3728]\]. There has been little research on *IL1R1* gene polymorphism and LDH.

For the *IL1R1* gene, Ren et al. \[[@b15-medscimonit-25-3728]\] explored the association of the *IL1R1* polymorphism (rs10490571, rs956730, and rs3917225) with tuberculosis risk. Xie et al. \[[@b16-medscimonit-25-3728]\] revealed the association between the *IL1R1* gene (rs10490571, rs12712127, rs956730, rs3917225, and rs3917318) and IgA nephropathy. Na et al. \[[@b17-medscimonit-25-3728]\] analyzed the association between the *IL1R1* gene and knee arthritis. However, the relationship between *IL1R1* and LDH has not been reported, so this study aimed to investigate the association between 5 SNPs (rs10490571, rs12712127, rs956730, rs3917225, and rs3917318) within *IL1R1* gene and LDH susceptibility in a Chinese Han population from northwest China. Our study will provide more significant evidence for further understanding of the LDH pathogenesis.

Material and Methods
====================

Study participants
------------------

A case-control study involving a Chinese study population of 498 LDH patients and 463 controls was conducted at the Second Affiliated Hospital of Inner Mongolia Medical University and the Hohhot First Hospital. Inclusion criteria for LDH patients were: patients with typical clinical symptoms who were diagnosed with LDH by imaging studies such as computed tomography (CT), or magnetic resonance imaging (MRI). Symptoms of LDH included: 1) low back pain; 2) partial lumbar spine pain and local typical sciatica; 3) differences in straight leg elevation test and protuberance test; 4) range of LDH. Exclusion criteria for LDH patients were: patients with blood diseases, autoimmune diseases, tumors, trauma, rheumatoid arthritis, and related lumbar spine diseases, including lumbar spinal stenosis, congenital dysplasia of the spine, intraspinal tumor, spondylolisthesis, etc. \[[@b18-medscimonit-25-3728]\].

The control group enrolled healthy volunteer with no physical history of sciatica and low back pain. The inclusion criteria of the control group were: 1) no history of waist and leg pain, family history; 2) no trauma, scoliosis, spondylolisthesis, osteoarthritis, rheumatism, rheumatoid arthritis, spinal instability; 3) no history of infection or cancer. All the participants were genetically unrelated ethnic Han Chinese and provided written informed consent for their participation in the present study. The protocols for this study were approved by the ethics committee of the Institutional Review Board of the Second Affiliated Hospital of Inner Mongolia Medical University.

SNP genotyping
--------------

We selected 5 candidate polymorphisms (rs10490571, rs12712127, rs956730, rs3917225, and rs3917318) in *IL1R1* with minor allele frequency (MAF) more than 0.05 based on the global population from 1000 Genome Projects (*<http://www.internationalgenome.org/>*). Then we used Regulome DB (*<http://www.regulomedb.org>*/) and HaploReg v4.1 (*<https://pubs.broadinstitute.org/mammals/haploreg/haploreg.php>*) to predict SNP function \[[@b19-medscimonit-25-3728]\]. Genomic DNA was prepared from peripheral blood samples using the Whole Blood Genomic DNA Extraction Kit (GoldMag Co. Ltd., Xi'an city, Shaanxi, China) according to the manufacturer's instructions. DNA concentrations were measured by NanoDrop 2000 (Thermo Scientific, Waltham, MA, USA). Primers for amplification process and single base extension reactions were designed using the Assay Design Suite V2.0 (*<https://agenacx.com/online-tools/>*). SNP genotyping was performed by Agena MassARRAY iPLEX (Agena Bioscience, San Diego, CA, USA) \[[@b20-medscimonit-25-3728]\]. Genotyping results were output by Agena Bioscience TYPER version 4.0 software \[[@b21-medscimonit-25-3728]\].

Statistical analysis
--------------------

We used Microsoft Excel 2016 and SPSS 21.0 (SPSS, Chicago, IL, USA) for statistical analyses. the Student's *t*-test and χ^2^ test were applied to assess the differences in the distribution of age and gender between cases and controls. Allele frequencies of each SNP were analyzed by χ^2^ test to evaluate whether these polymorphisms departures from Hardy-Weinberg equilibrium (HWE). The χ^2^ test was used to compare the differences in SNPs allele and genotype frequencies between patients and controls. Multiple genetic model analyses (codominant, dominant, recessive and log-additive) were applied using SNPStats software (*<http://bioinfo.iconcologia.net/snpstats/start.htm>*) to appraise the link between SNPs and LDH risk. Then we conducted the stratification analysis according to age and gender to estimate the association between SNPs genotype and LDH risk. Odds ratios (OR) and 95% confidence intervals (CI) were calculated by logistic regression analyses, the wild-type allele was used as a reference. Finally, we used Haploview software (version 4.2) to construct haplotype and to estimate the pairwise linkage disequilibrium, the SHEsis software platform (*<http://analysis.bio-x.cn/myAnalysis.php>*) was used to estimate the association between haplotype and LDH risk \[[@b22-medscimonit-25-3728]\]. All *P*-values were 2-sided, and *P*\<0.05 was considered to have significant differences. All of the aforementioned statistical analyses were performed on 5 SNPs (rs10490571, rs12712127, rs956730, rs3917225, and rs3917318) of the *IL1R1* gene.

Results
=======

Demographic characteristics
---------------------------

The study included 498 LDH patients (200 female and 298 male) and 463 controls (198 female and 265 male). No significant difference in gender and age was observed between the patient and control groups (*P*\>0.05). The mean age ± standard deviation of 498 patients (age ≤50 years, 233 cases; age \>50 years, 265 cases) was 50.27±12.53 years, and the average age of control group (age ≤50 years, 216 cases; age \>50 years, 247 cases) was 50.65±11.8 years ([Table 1](#t1-medscimonit-25-3728){ref-type="table"}).

Basic information and allele frequencies of *IL1R1* polymorphisms are shown in [Table 2](#t2-medscimonit-25-3728){ref-type="table"}. The genotype distribution of all SNPs in control participants met the HWE (*P*\>0.05). To evaluate the function of the selected SNPs, we use Regulome DB Score and HaploReg for database analysis, results in [Table 2](#t2-medscimonit-25-3728){ref-type="table"} show that Regulome DB score of rs10490571 *loci* was 2b, and show that the SNP might affected the binding; the score of rs956730 was 4 and other 3 SNPs (rs12712127, rs3917225,and rs3917318) had Regulome DB score of 5, which were classified as "minimal binding evidence". HaploReg function annotation results revealed that SNPs associated with LDH risk were successfully predicted to have biological functions, the results showed that rs10490571 might be a functional *loci* of DNAse, proteins bound, motifs changed, and selected eQTL hits; rs12712127 had the potential function of selected eQTL hits; rs956730 might have the function of DNAse and motifs changed; rs3917225 had the potential motifs changed and selected eQTL hits functions; and rs3917318 might have the function of DNAse and Motifs changed. Genotype frequencies of the *IL1R1* polymorphisms were described in [Supplementary Table 1](#s1-medscimonit-25-3728){ref-type="supplementary-material"}. Unfortunately, there were no differences between SNPs in the *IL1R1* gene and LDH risk (all *P*\>0.05).

SNPs and the risk of LDH
------------------------

In stratified analysis by gender, we found that the SNP *IL1R1* rs956730 was not significant in females, while it was statistically significant in males ([Table 3](#t3-medscimonit-25-3728){ref-type="table"}). The frequency of "AA" genotype in *IL1R1* rs956730 was significantly different between patients and controls in males (9.1% versus 3.4%). Further, *IL1R1* rs956730 was related to an increased risk of LDH based on the mutant homozygous genotype "AA" in the codominant model (adjusted by age, AA versus GG, OR=2.37, 95% CI: 1.08--5.21, *P*=0.001) and in the recessive model (adjusted by age, GG/GA versus AA, OR=2.82, 95% CI: 1.30--6.12, *P*=0.005) in males. While the heterozygous genotype "AG" in the codominant model (adjusted by age, AG versus GG, OR=0.65, 95% CI: 0.46--0.92, *P*=0.001) of rs956730 was associated with a reduced risk of LDH in males. There was no significant association between polymorphisms in the remaining 4 *loci* (rs10490571, rs12712127, rs3917225, and rs3917318) and LDH susceptibility in gender-stratified analysis (all *P*\>0.05, [Supplementary Table 2](#s2-medscimonit-25-3728){ref-type="supplementary-material"}).

In stratified analysis by age, we found that the SNP rs10490571 was not significant among people under 50 years of age, but was statistically significant in people older than 50 years of age ([Table 4](#t4-medscimonit-25-3728){ref-type="table"}). The frequency of "TT" genotype in *IL1R1* rs10490571 was differed significantly between patients and controls in people older than 50 years of age (5.3% versus 1.6%). And rs10490571 was correlated with an increased risk of LDH based on the results of the recessive model (adjusted by gender and age, CC/CT versus TT, OR=3.43, 95% CI: 1.11--10.57, *P*=0.020) in people older than 50 years of age. There was no significant association between polymorphisms in the other 4 *loci* (rs12712127, rs956730, rs3917225, and rs3917318) on the *IL1R1* gene and susceptibility to LDH in age-stratified analysis (all *P*\>0.05, [Supplementary Table 3](#s3-medscimonit-25-3728){ref-type="supplementary-material"}).

LDH and haplotypes at chromosome 2q12.1
---------------------------------------

Finally, 2 *IL1R1* polymorphisms (rs10450571-rs12712127) mapped to a 9kb LD block and showed 2 haplotypes with frequencies of more than 0.05 in our study participants ([Table 5](#t5-medscimonit-25-3728){ref-type="table"}). The red squares of the *IL1R1* LD block presented significant linkage between the 2 SNPs in [Figure 1](#f1-medscimonit-25-3728){ref-type="fig"}. Unfortunately, there was no significant difference among any of the *IL1R1* haplotype frequencies in patients and controls.

Discussion
==========

It is well known that genetic factors play an important role in the development of LDH. However, only a few genetic risk factors for LDH have been identified in Chinese population. In our case-control study, we genotyped 5 SNPs of the *IL1R1* gene and evaluated their association with LDH risk in the Han population of northwest China. Our data showed that the SNPs rs956730 and rs10490571 were significantly associated with LDH susceptibility.

LDH is a degenerative disease that can cause neuropathic symptoms of spinal cord pain syndrome and nerve root ischemia. In addition, a variety of inflammatory related factors can also induce lumbar disc degeneration and nerve root pain, further accelerate inflammation and intervertebral disc formation, this vicious circle will deepen the lumbar disc degeneration and pain. *IL1* is a protein coding gene, the protein encoded by this gene is a member of the interleukin 1 (*IL1*) cytokine family. This cytokine is a pleiotropic cytokine involved in various immune responses \[[@b23-medscimonit-25-3728]\], inflammatory processes \[[@b24-medscimonit-25-3728]\], and hematopoiesis \[[@b25-medscimonit-25-3728]\]. Inflammation is regulated by a series of corresponding receptors, downstream signaling pathways and cytokines. It has been suggested that the polymorphism of *IL1* genes is associated with rheumatoid arthritis \[[@b26-medscimonit-25-3728]\]. Moen et al. \[[@b27-medscimonit-25-3728]\] indicated that*IL1* was associated with chronic lumbar radicular pain. *IL1R1* belongs to *IL1* family, and *IL1R1* has reported to be involved in inflammatory reactions \[[@b13-medscimonit-25-3728]\]. Latiano et al. \[[@b28-medscimonit-25-3728]\] indicated that the genetic polymorphism of *IL1R1* was correlated with inflammatory bowel disease. Na et al. \[[@b17-medscimonit-25-3728]\] revealed that *IL1R1* gene polymorphisms are associated with knee osteoarthritis risk. Therefore, we present a reasonable hypothesis related to *IL1R1* in the pathogenesis of LDH. And in this study, we found that 2 SNPs (rs956730 and rs10490571) mutations in the *IL1R1* gene are associated with susceptibility to LDH, validating our hypothesis.

In addition, there was a meaningful finding in our research that gender and age play important roles in the development of LDH. Within the disc structure, collagen is essential for the biomechanical stability and the overall property. Zhang et al. \[[@b29-medscimonit-25-3728]\] found that age was inversely correlated with collagen synthesis, suggested that with the increase of age, the decreased collagen synthesis will affect the stability of intervertebral disc structure and lead to the occurrence of related diseases such as LDH. Boos et al. \[[@b30-medscimonit-25-3728]\] reported that intervertebral disc degeneration is part of aging process. Compared with young people, the collagenous matrix in the discs of the elderly was significant changed \[[@b31-medscimonit-25-3728]\]. Our studies showed that the recessive model of rs10490571 in the *IL1R1* gene was associated with an increased LDH risk among people older than 50 years of age. It was consistent with previous research that hinted that people older than 50 years of age with rs10490571 mutations in *IL1R1* were more likely to develop LDH. Moreover, according to the results of the Regulome DB database, it was speculated that rs10490571 is a binding site for various proteins such as HNF4A, MYBL2 and CDX2. CDX2 has been found to be involved in the body's immune response \[[@b32-medscimonit-25-3728]\], and differences in CDX2 expression might lead to disease. Thus, we hypothesized that the rs10490571 mutation might affect the binding of CDX2 to cause differential expression of the protein, leading to the occurrence of LDH. Furthermore, our research indicated that the "AA" genotype model and recessive model of rs956730 in the *IL1R1* gene was associated with increased LDH risk in males. This was similar to the research Miller et al. \[[@b33-medscimonit-25-3728]\] conducted, who found that disc degeneration occurred significantly more often in males. Min et al. \[[@b34-medscimonit-25-3728]\] proved that LDH was more likely to occur in males. The reason might be that males tend to perform heavier work and have a higher body weight than females. In addition, the Regulome DB database suggested that rs956730 is a binding site for the POLR2A protein, and it has been reported that POLR2A is involved in neuroinflammatory responses \[[@b35-medscimonit-25-3728],[@b36-medscimonit-25-3728]\]. Therefore, we speculated that the pathogenesis of LDH might be related to the change of POLR2A expression caused by rs956730 locus variation.

Unfortunately, we did not find a significant association between the other 3 SNPs (rs12712127, rs3917225, and rs3917318) on the *IL1R1* gene and susceptibility to LDH. Na et al. \[[@b17-medscimonit-25-3728]\] also found that they were not significantly associated with knee arthritis. The reason for this phenomenon might be the limitations of the sample size of this study. In future studies, we will increase the sample size for further verification.

Conclusions
===========

Our study demonstrated a significant association between the *IL1R1* gene polymorphism and susceptibility to LDH in the Han population of northwestern China, especially the mutations of rs956730 and rs10490571 were found to be significantly associated with the susceptibility of LDH, which might provide new insights into therapeutic targets for LDH.

Ethics approval and consent to participate
------------------------------------------

This study was approved by the ethics committee of The Second Affiliated Hospital of Inner Mongolia Medical University. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. All participants were informed both in writing and verbally to the procedures and purpose of the study and signed informed consent documents.

Supplementary Tables
====================

###### 

*IL1R1* SNP genotypes and the risk of LDH.

                 Model         Genotype      Control             Case                Crude   Adjust by gender and age           
  -------------- ------------- ------------- ------------------- ------------------- ------- -------------------------- ------- -------
  rs10490571     Codominant    CC            323 (69.8%)         339 (68.1%)         1.00    0.160                      1.00    0.160
  CT             127 (27.4%)   133 (26.7%)   1.00 (0.75--1.33)   1.00 (0.75--1.34)                                              
  TT             13 (2.8%)     26 (5.2%)     1.91 (0.96--3.77)   1.90 (0.96--3.77)                                              
  Dominant       CC            323 (69.8%)   339 (68.1%)         1.00                0.570   1.00                       0.560   
  CT/TT          140 (30.2%)   159 (31.9%)   1.08 (0.82--1.42)   1.09 (0.83--1.43)                                              
  Recessive      CC/CT         450 (97.2%)   472 (94.8%)         1.00                0.056   1.00                       0.056   
  TT             13 (2.8%)     26 (5.2%)     1.91 (0.97--3.76)   1.90 (0.97--3.75)                                              
  Log-additive   \-\--         \-\--         \-\--               1.14 (0.91--1.44)   0.250   1.15 (0.91--1.44)          0.250   
  rs12712127     Codominant    AA            314 (68.3%)         322 (65.0%)         1.00    0.540                      1.00    0.530
  AG             99 (21.5%)    114 (23%)     1.12 (0.82--1.53)   1.13 (0.83--1.55)                                              
  GG             47 (10.2%)    59 (11.9%)    1.22 (0.81--1.85)   1.22 (0.81--1.84)                                              
  Dominant       AA            314 (68.3%)   322 (65%)           1.00                0.290   1.00                       0.280   
  AG/GG          146 (31.7%)   173 (35.0%)   1.16 (0.88--1.51)   1.16 (0.89--1.52)                                              
  Recessive      AA/AG         413 (89.8%)   436 (88.1%)         1.00                0.400   1.00                       0.420   
  GG             47 (10.2%)    59 (11.9%)    1.19 (0.79--1.78)   1.18 (0.79--1.78)                                              
  Log-additive   \-\--         \-\--         \-\--               1.11 (0.92--1.34)   0.270   1.11 (0.92--1.34)          0.260   
  rs956730       Codominant    GG            246 (53.2%)         280 (56.2%)         1.00    0.120                      1.00    0.120
  AG             191 (41.3%)   179 (35.9%)   0.82 (0.63--1.07)   0.82 (0.63--1.08)                                              
  AA             25 (5.4%)     39 (7.8%)     1.37 (0.81--2.33)   1.38 (0.81--2.34)                                              
  Dominant       GG            246 (53.2%)   280 (56.2%)         1                   0.350   1                          0.360   
  AG/AA          216 (46.8%)   218 (43.8%)   0.89 (0.69--1.14)   0.89 (0.69--1.15)                                              
  Recessive      GG/AG         437 (94.6%)   459 (92.2%)         1.00                0.130   1.00                       0.130   
  AA             25 (5.4%)     39 (7.8%)     1.49 (0.88--2.50)   1.49 (0.89--2.50)                                              
  Log-additive   \-\--         \-\--         \-\--               0.99 (0.80--1.21)   0.890   0.99 (0.80--1.21)          0.900   
  rs3917225      Codominant    AA            204 (44.2%)         219 (44.0%)         1.00    0.780                      1.00    0.800
  AG             200 (43.3%)   209 (42.0%)   0.97 (0.74--1.28)   0.98 (0.75--1.29)                                              
  GG             58 (12.6%)    70 (14.1%)    1.12 (0.76--1.67)   1.12 (0.75--1.67)                                              
  Dominant       AA            204 (44.2%)   219 (44.0%)         1.00                0.960   1.00                       0.930   
  AG/GG          258 (55.8%)   279 (56.0%)   1.01 (0.78--1.30)   1.01 (0.78--1.31)                                              
  Recessive      AA/AG         404 (87.5%)   428 (85.9%)         1.00                0.490   1.00                       0.510   
  GG             58 (12.6%)    70 (14.1%)    1.14 (0.78--1.66)   1.13 (0.78--1.65)                                              
  Log-additive   \-\--         \-\--         \-\--               1.04 (0.86--1.24)   0.710   1.04 (0.86--1.24)          0.700   
  rs3917318      Codominant    AA            136 (29.4%)         126 (25.3%)         1.00    0.090                      1.00    0.087
  AG             204 (44.2%)   255 (51.2%)   1.35 (1.00--1.83)   1.35 (1.00--1.83)                                              
  GG             122 (26.4%)   117 (23.5%)   1.04 (0.73--1.47)   1.03 (0.73--1.47)                                              
  Dominant       AA            136 (29.4%)   126 (25.3%)         1.00                0.150   1.00                       0.150   
  AG/GG          326 (70.6%)   372 (74.7%)   1.23 (0.93--1.64)   1.23 (0.93--1.64)                                              
  Recessive      AA/AG         340 (73.6%)   381 (76.5%)         1.00                0.300   1.00                       0.290   
  GG             122 (26.4%)   117 (23.5%)   0.86 (0.64--1.15)   0.85 (0.64--1.14)                                              
  Log-additive   \-\--         \-\--         \-\--               1.02 (0.86--1.22)   0.790   1.02 (0.86--1.22)          0.800   

OR -- odds ratio; CI -- confidence interval*. P*\<0.05 indicates statistical significance.

###### 

Stratified analysis between *IL1R1* SNPs and gender associated with LDH risk.

                 Model        Genotypes   Male                Adjusted by age OR (95%CI)   *P*     Female              Adjusted by age OR (95%CI)   *P*                         
  -------------- ------------ ----------- ------------------- ---------------------------- ------- ------------------- ---------------------------- ------------------- ------- -------
  rs10490571     Codominant   C/C         193                 198                          1.00    0.230               130                          141                 1.00    0.047
  C/T            63           85          1.31 (0.90--1.93)   64                           48      0.70 (0.45--1.09)                                                            
  T/T            9            15          1.62 (0.69--3.80)   4                            11      2.58 (0.80--8.30)                                                            
  Dominant       C/C          193         198                 1.00                         0.100   130                 141                          1.00                0.320   
  C/T-T/T        72           100         1.35 (0.94--1.94)   68                           59      0.81 (0.53--1.23)                                                            
  Recessive      C/C-C/T      256         283                 1.00                         0.330   194                 189                          1.00                0.060   
  T/T            9            15          1.51 (0.65--3.51)   4                            11      2.87 (0.90--9.17)                                                            
  Log-additive   \-\--        \-\--       \-\--               1.30 (0.96--1.75)            0.088   \-\--               \-\--                        0.96 (0.67--1.38)   0.830   
  rs12712127     Codominant   A/A         186                 189                          1.00    0.180               128                          133                 1.00    0.730
  A/G            49           71          1.43 (0.94--2.17)   50                           43      0.84 (0.52--1.35)                                                            
  G/G            27           37          1.35 (0.79--2.30)   20                           22      1.06 (0.55--2.03)                                                            
  Dominant       A/A          186         189                 1.00                         0.064   128                 133                          1.00                0.620   
  A/G-G/G        76           108         1.40 (0.98--2.00)   70                           65      0.90 (0.59--1.37)                                                            
  Recessive      A/A-A/G      235         260                 1.00                         0.430   178                 176                          1.00                0.760   
  G/G            27           37          1.24 (0.73--2.10)   20                           22      1.11 (0.58--2.10)                                                            
  Log-additive   \-\--        \-\--       \-\--               1.22 (0.96--1.56)            0.100   \-\--               \-\--                        0.97 (0.73--1.30)   0.840   
  rs3917225      Codominant   A/A         126                 126                          1.00    0.410               78                           93                  1.00    0.310
  A/G            104          127         1.22 (0.85--1.75)   96                           82      0.72 (0.47--1.10)                                                            
  G/G            34           45          1.32 (0.80--2.20)   24                           25      0.87 (0.46--1.64)                                                            
  Dominant       A/A          126         126                 1.00                         0.200   78                  93                           1.00                0.160   
  A/G-G/G        138          172         1.25 (0.89--1.74)   120                          107     0.75 (0.50--1.12)                                                            
  Recessive      A/A-A/G      230         253                 1.00                         0.450   174                 175                          1.00                0.930   
  G/G            34           45          1.20 (0.74--1.94)   24                           25      1.03 (0.56--1.87)                                                            
  Log-additive   \-\--        \-\--       \-\--               1.17 (0.92--1.48)            0.200   \-\--               \-\--                        0.86 (0.65--1.15)   0.320   
  rs3917318      Codominant   G/G         76                  68                           1.00    0.150               61                           46                  1.00    0.200
  A/G            113          150         1.48 (0.99--2.23)   91                           105     1.53 (0.95--2.46)                                                            
  A/A            75           80          1.19 (0.76--1.88)   46                           49      1.41 (0.81--2.45)                                                            
  Dominant       G/G          76          68                  1.00                         0.110   61                  46                           1.00                0.079   
  A/G-A/A        188          230         1.37 (0.94--2.00)   137                          154     1.49 (0.95--2.33)                                                            
  Recessive      G/G-A/G      189         218                 1.00                         0.670   152                 151                          1.00                0.780   
  A/A            75           80          0.92 (0.64--1.34)   46                           49      1.07 (0.67--1.69)                                                            
  Log-additive   \-\--        \-\--       \-\--               1.09 (0.87--1.36)            0.480   \-\--               \-\--                        1.19 (0.91--1.58)   0.210   

OR -- odds ratio; CI -- confidence interval*. P*\<0.05 indicates statistical significance.

###### 

Stratified analysis between IL1R1 SNPs and age associated with LDH risk.

                 Model        Genotypes   ≤50                 Adjusted by age OR (95%CI)   *P*     \>50                Adjusted by age OR (95%CI)   *P*                         
  -------------- ------------ ----------- ------------------- ---------------------------- ------- ------------------- ---------------------------- ------------------- ------- -------
  rs12712127     Codominant   A/A         147                 149                          1.00    0.340               167                          173                 1.00    0.370
  A/G            36           52          1.43 (0.88--2.32)   63                           62      0.96 (0.63--1.44)                                                            
  G/G            30           32          1.06 (0.61--1.83)   17                           27      1.54 (0.81--2.94)                                                            
  Dominant       A/A          147         149                 1.00                         0.250   167                 173                          1.00                0.680   
  A/G-G/G        66           84          1.26 (0.85--1.87)   80                           89      1.08 (0.75--1.57)                                                            
  Recessive      A/A-A/G      183         201                 1.00                         0.930   230                 235                          1.00                0.160   
  G/G            30           32          0.98 (0.57--1.67)   17                           27      1.56 (0.83--2.94)                                                            
  Log-additive   \-\--        \-\--       \-\--               1.10 (0.85--1.42)            0.480   \-\--               \-\--                        1.13 (0.86--1.49)   0.360   
  rs956730       Codominant   G/G         112                 125                          1.00    0.550               134                          155                 1.00    0.180
  A/G            91           90          0.89 (0.60--1.32)   100                          89      0.77 (0.53--1.11)                                                            
  A/A            12           18          1.36 (0.62--2.94)   13                           21      1.40 (0.68--2.91)                                                            
  Dominant       G/G          112         125                 1.00                         0.770   134                 155                          1.00                0.340   
  A/G-A/A        103          108         0.95 (0.65--1.37)   113                          110     0.84 (0.59--1.20)                                                            
  Recessive      G/G-A/G      203         215                 1.00                         0.350   234                 244                          1.00                0.220   
  A/A            12           18          1.42 (0.67--3.03)   13                           21      1.56 (0.76--3.18)                                                            
  Log-additive   \-\--        \-\--       \-\--               1.02 (0.76--1.38)            0.890   \-\--               \-\--                        0.96 (0.73--1.27)   0.780   
  rs3917225      Codominant   A/A         93                  105                          1.00    0.920               111                          114                 1.00    0.410
  A/G            89           95          0.95 (0.64--1.43)   111                          114     1.01 (0.69--1.46)                                                            
  G/G            33           33          0.89 (0.51--1.55)   25                           37      1.45 (0.82--2.57)                                                            
  Dominant       A/A          93          105                 1.00                         0.730   111                 114                          1.00                0.640   
  A/G-G/G        122          128         0.94 (0.64--1.36)   136 (55.1%)                  151     1.09 (0.77--1.54)                                                            
  Recessive      A/A-A/G      182         200                 1.00                         0.720   222                 228                          1.00                0.180   
  G/G            33           33          0.91 (0.54--1.54)   25                           37      1.44 (0.84--2.48)                                                            
  Log-additive   \-\--        \-\--       \-\--               0.95 (0.73--1.23)            0.680   \-\--               \-\--                        1.14 (0.88--1.47)   0.320   
  rs3917318      Codominant   A/A         66                  53                           1.00    0.16                70                           73                  1.00    0.140
  A/G            94           117         1.55 (0.98--2.43)                                110     138                 1.21 (0.80--1.83)                                        
  G/G            56           63          1.40 (0.84--2.33)                                66      54                  0.78 (0.48--1.27)                                        
  Dominant       A/A          66          53                  1.00                         0.064   70                  73                           1.00                0.810   
  A/G-G/G        150          180         1.49 (0.98--2.27)                                176     192                 1.05 (0.71--1.54)                                        
  Recessive      A/A-A/G      160         170                 1.00                         0.800   180                 211                          1.00                0.078   
  G/G            56           63          1.06 (0.69--1.61)                                66      54                  0.69 (0.46--1.04)                                        
  Log-additive   \-\--        \-\--       \-\--               1.18 (0.91--1.53)            0.200   \-\--               \-\--                        0.90 (0.70--1.14)   0.370   

OR -- odds ratio; CI -- confidence interval.*P*\<0.05 indicates statistical significance.
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###### 

Distributions of age and gender in LDH patients and controls.

  Variable   Cases           \%              Controls   \%     *P*
  ---------- --------------- --------------- ---------- ------ -------
  Total      498                             463               
  Gender                                                       0.413
   Female    200             40.2            198        42.8   
   Male      298             59.8            265        57.2   
  Age                                                          0.978
   ≤50       233             46.8            216        46.7   
   \>50      265             53.2            247        53.3   
  Mean ±SD   50.27 ± 12.53   50.65 ± 11.80                     

*P*\<0.05 indicates statistical significance.

###### 

Basic characteristics and allele frequencies of the 5 SNPs.

  SNP_ID       Genes     Chr.     Allele (A/B)   MAF     OR (95%CI)   *P*                 Regulome DB Score   Function   
  ------------ --------- -------- -------------- ------- ------------ ------------------- ------------------- ---------- -----------------------------------------------------------
  rs10490571   *IL1R1*   2q12.1   T/C            0.186   0.165        1.15 (0.91--1.45)   0.238               2b         DNAse, Proteins bound, Motifs changed, Selected eQTL hits
  rs12712127   *IL1R1*   2q12.1   G/A            0.234   0.210        1.15 (0.93--1.43)   0.197               4          Selected eQTL hits
  rs956730     *IL1R1*   2q12.1   A/G            0.258   0.261        0.98 (0.80--1.20)   0.889               5          DNAse, Motifs changed
  rs3917225    *IL1R1*   2q12.1   G/A            0.350   0.342        1.03 (0.86--1.25)   0.699               5          Motifs changed, Selected eQTL hits
  rs3917318    *IL1R1*   2q12.1   G/A            0.491   0.485        1.02 (0.86--1.22)   0.789               5          DNAse, Motifs changed

SNP -- single nucleotide polymorphism; Chr. -- chromosome; A/B -- minor/major; MAF -- minor allele frequency; OR -- odds ratio; 95%CI -- 95% confidence interval. Score 2b indicated the SNP *loci* is likely to affect binding; score 4 and 5 indicated minimal binding evidence.*P*\<0.05 indicates statistical significance.

###### 

Stratified analysis between*IL1R1* SNPs and gender associated with LDH risk.

                 Model        Genotype   Male                    Adjusted by age OR (95%CI)   *P*         Female              Adjusted by age OR (95%CI)   *P*                         
  -------------- ------------ ---------- ----------------------- ---------------------------- ----------- ------------------- ---------------------------- ------------------- ------- -------
  rs956730       Codominant   GG         139                     176                          1.00        **0.001**           107                          104                 1.00    0.580
  AG             116          95         **0.65 (0.46--0.92)**   75                           84          1.14 (0.75--1.73)                                                            
  AA             9            27         **2.37 (1.08--5.21)**   16                           12          0.76 (0.34--1.69)                                                            
  Dominant       GG           139        176                     1.00                         0.130       107                 104                          1.00                0.720   
  AG/AA          125          122        0.77 (0.55--1.08)       91                           96          1.07 (0.72--1.60)                                                            
  Recessive      GG/AG        255        271                     1.00                         **0.005**   182                 188                          1.00                0.400   
  AA             9            27         **2.82 (1.30--6.12)**   16                           12          0.72 (0.33--1.56)                                                            
  Log-additive   \-\--        \-\--      \-\--                   0.98 (0.75--1.28)            0.880       \-\--               \-\--                        0.99 (0.72--1.36)   0.950   

OR -- odds ratio; CI -- confidence interval*. P*\<0.05 indicates statistical significance. Bold values indicate a significant difference.

###### 

Stratified analysis between *IL1R1* SNPs and age associated with LDH risk.

                 Model        Genotype   ≤50                 Adjusted by age OR (95%CI)   *P*     \>50                     Adjusted by age OR (95%CI)   *P*                             
  -------------- ------------ ---------- ------------------- ---------------------------- ------- ------------------------ ---------------------------- ------------------- ----------- -------
  rs956730       Codominant   CC         153                 157                          1.00    0.700                    170                          182                 1.00        0.054
  CT             54           64         1.16 (0.76--1.77)   73                           69      0.89 (0.60--1.31)                                                                     
  TT             9            12         1.31 (0.54--3.20)   4                            14      3.31 (1.07--10.26)                                                                    
  Dominant       CC           153        157                 1.00                         0.420   170                      182                          1.00                0.950       
  CT/TT          63           76         1.18 (0.79--1.76)   77                           83      1.01 (0.70--1.47)                                                                     
  Recessive      CC/CT        207        221                 1.00                         0.610   243                      251                          1.00                **0.019**   
  TT             9            12         1.26 (0.52--3.05)   4                            14      **3.43 (1.11--10.57)**                                                                
  Log-additive   \-\--        \-\--      \-\--               1.15 (0.83--1.60)            0.400   \-\--                    \-\--                        1.14 (0.83--1.57)   0.410       

OR -- odds ratio; CI -- confidence interval.*P*\<0.05 indicates statistical significance. Bold values indicate a significant difference.

###### 

*IL1R1* haplotype frequencies and the association with LDH risk.

  rs10490571   rs12712127   Freq    Adjusted by age and gender OR (95%CI)   *P*-value
  ------------ ------------ ------- --------------------------------------- -----------
  C            A            0.778   1.00                                    \-\--
  T            G            0.175   1.15 (0.91--1.45)                       0.230
  C            G            0.047   1.01 (0.68--1.52)                       0.940

OR -- odds ratio; CI -- confidence interval. *P*\<0.05 indicates statistical significance.
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